- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07579351
Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2 (CLEAR 2)
Corticosteroid Lumbar Epidural Analgesia for Radicular Pain (C.L.E.A.R) 2 - A Randomized, Double-blind, Active Comparator and Placebo-controlled, Multicenter, Safety and Efficacy Trial of SP-102
This is a research study of SP-102, an experimental medication designed to relieve pain in patients with moderate to severe sciatica (pain in the lower back, hips, buttocks and legs). SP-102, placebo (a medication that looks like SP-102 but does not contain any active ingredient), or an active comparator (dexamethasone sodium phosphate) is given once by the participant's healthcare professional. If a participant meets qualifications, each participant will have the option of receiving one supplemental open-label injection of SP-102, greater than four weeks and up to twenty weeks after their first injection.
The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain versus placebo. The study will also measure how well SP-102 relieves pain versus an active comparator medication (dexamethasone sodium phosphate). The study will also investigate the side effects of SP-102.
연구 개요
상태
상세 설명
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Senior Director Clinical Operations
- 전화번호: 1-650-386-6709
- 이메일: clinicaltrials@semnurpharma.com
연구 연락처 백업
- 이름: Dmitri Lissin, Study Director, MD
- 전화번호: 1-650-422-7515
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
Main Inclusion Criteria:
- Able and willing to read, write, and understand the English language and provide English language written informed consent prior to beginning any study procedures.
- Age 18 to 75 years (inclusive) at the Screening Visit.
- A diagnosis of lumbosacral radicular pain (sciatica) present for at least 6 weeks and not more than 9 months prior to the Screening Visit.
- Clinical symptoms consistent with the imaging (MRI)
- Agrees to follow study-specific medication requirements.
- If sexually active and a female of child-bearing potential or a male capable of bearing a child, agrees to use an effective method of birth control during the study.
- Has reviewed all study specific materials and has, in the opinion of the Investigator, the abilities to understand and appropriately complete all study procedures.
Day 1 Inclusion:
As calculated by the eDiary system, during the 7 days (D-7 to D-1) immediately prior to the Baseline Visit, the participant:
- Completed the current, worst, and daily average NPRS scores (in the affected leg, non-affected leg, and lower back) in the eDiary on at least 6 out of the 7 days during the Baseline Period.
- Meets the NPRS average daily pain score criteria,
- Has a mean (at Baseline Visit) NPRS worst pain score in the affected leg that is greater than the mean worst pain score in lower back.
Participant continues to demonstrate a clear understanding of how to complete the eDiary.
Participant remains an appropriate candidate for trial participation in the opinion of the Investigator.
Participant continues to meet all the screening inclusion criteria and none of the exclusion criteria. -
Exclusion Criteria:
- Has a body mass index ≥40 kg/m2.
- Has radiologic evidence of a condition that would compromise study outcomes:
Spinal cord tumor (intra- or extradural) or hematoma. Epidural or intrathecal abscess. Systemic infection.
- Has ever had lumbosacral back surgery or plans to undergo spine surgical intervention while in the study.
- Has been diagnosed with insulin dependent diabetes mellitus.
- Presence of any other disorder, condition or circumstance (including secondary gain) that, in the opinion of the Investigator, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments.
- Use of any investigational drug and/or device within 30 days, or is scheduled to receive an investigational drug other than blinded study drug during this study.
- Has any contradiction to performing MRI (such as coronary pacemakers and implantable cardioverter-defibrillators [ICDs], metallic foreign bodies, neuro and spinal cord stimulators).
- Has history of malignancy or evidence of malignancy, within 5 years of Screening Visit.
- Has significant motor impairment
- Has regular use of opioid doses > 30 mg morphine equivalents per day for more than 2 days per week in the 30 days prior to the Screening Visit.
- Involvement in an ongoing worker's compensation claim, disability claim, or litigation related to any pain problem, receiving payments for a settled claim, awaiting pending payment for a settled claim, or any potential secondary gain in the opinion of the Investigator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약 비교기
|
One injection
|
|
실험적: SP-102
|
One Injection
|
|
활성 비교기: dexamethasone sodium phosphate
|
One injection
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean change from baseline to W4 in the mean NPRS average daily pain score.
기간: Day 1 to week 4
|
The Numeric Pain Rating Scale (NPRS) is a self-reported scale assessing average pain intensity over the past 24 hours in the affected leg.
Possible scores range from 0-10 (0 is no pain, 10 is worst pain imaginable) Change from baseline (mean of the scores recorded on the 7 days [D-7 to D-1] immediately prior to the P1 Injection Day) in mean NPRS average daily pain score in the affected leg over 4 weeks (i.e., W1, W2, W3, W4) for SP-102 versus placebo.
|
Day 1 to week 4
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean change in ODI total score
기간: Day 1 to Week 4
|
The Oswestry disability index (ODI) is a validated, self-reported instrument that evaluates degree of disability (0-100, 0=No disability, 100=Maximum disability). Comparison is between SP-102 and placebo. |
Day 1 to Week 4
|
|
Patient Global Impression of Change
기간: Day 1 to week 4
|
The PGIC scores range from 1 (very much improved) through 7 (very much worse) as assessed by the participant.
|
Day 1 to week 4
|
|
Mean change in BPI-Pain Interference (BPI-PI) score from P1 Baseline (D1) to P1 W4 for SP-102 versus placebo.
기간: Day 1 to week 4
|
Participants rate their worst, least, average, and current pain intensity on a 0-10 numeric rating scale as it affects their daily functioning (0=does not interfere and 10=completely interferes).
|
Day 1 to week 4
|
|
Proportion of participants with a ≥ 30% improvement from P1 D1 to W4 in mean NPRS average daily pain score in the affected leg for SP-102 versus placebo.
기간: Day 1 to week 4
|
The Numeric Pain Rating Scale (NPRS) is a self-reported scale assessing average pain intensity over the past 24 hours in the affected leg.
Possible scores range from 0-10 (0 is no pain, 10 is worst pain imaginable) Change from baseline (mean of the scores recorded on the 7 days [D-7 to D-1] immediately prior to the P1 Injection Day) in mean NPRS average daily pain score in the affected leg over 4 weeks (i.e., W1, W2, W3, W4) for SP-102 versus placebo.
|
Day 1 to week 4
|
|
Proportion of participants with a ≥ 50% improvement from P1 D1 to W4 in mean NPRS average daily pain score in the affected leg for SP-102 versus placebo.
기간: Day 1 to week 4
|
The Numeric Pain Rating Scale (NPRS) is a self-reported scale assessing average pain intensity over the past 24 hours in the affected leg.
Possible scores range from 0-10 (0 is no pain, 10 is worst pain imaginable) Change from baseline (mean of the scores recorded on the 7 days [D-7 to D-1] immediately prior to the P1 Injection Day) in mean NPRS average daily pain score in the affected leg over 4 weeks (i.e., W1, W2, W3, W4) for SP-102 versus placebo.
|
Day 1 to week 4
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SP-102-05
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Lumbosacral Radicular 통증에 대한 임상 시험
-
Hasanuddin UniversityFaculty of Medicine, Gadjah Mada University; Sardjito General Hospital, Yogyakarta, Indonesia완전한
-
Yonsei University종료됨
-
Yonsei University완전한
-
Yonsei University완전한
-
Semnur Pharmaceuticals, Inc.Worldwide Clinical Trials; Scilex Pharmaceuticals, Inc.완전한
-
Scilex Pharmaceuticals, Inc.Worldwide Clinical Trials; Semnur Pharmaceuticals, Inc.완전한
-
Consano Bio모병좌골 신경통 | 좌골 신경근병증 | Lumbosacral Radiculopathy | 요천추 신경근 증후군 | Lumbosacral Radicular 통증 | 좌골 다리 통증호주
-
Chang Gung Memorial Hospital완전한
-
Medtronic Spinal and Biologics모집하지 않고 적극적으로
SP-102에 대한 임상 시험
-
Semnur Pharmaceuticals, Inc.Worldwide Clinical Trials; Scilex Pharmaceuticals, Inc.완전한
-
Scilex Pharmaceuticals, Inc.Worldwide Clinical Trials; Semnur Pharmaceuticals, Inc.완전한
-
The Dental Hospital of Zhejiang University School...모병
-
L&C BioPROMeDis모집하지 않고 적극적으로
-
Ruijin Hospital모병
-
JhpiegoBarcelona Institute for Global Health완전한
-
Pharmacosmos A/SICON plc모병
-
Morris Innovative IncorporatedDeborah Heart and Lung Center알려지지 않은